Three things to know:
1. The company’s subsidiary Kuros Biosciences BV also secured a patent for developing an osteoinductive calcium phosphate, further bolstering its orthobiologics portfolio.
2. Kuros develops Fibrin-PTH, a natural fibrin-based healing matrix with an immobilized targeted bone growth factor. It is designed to apply onto and around an intervertebral body fusion device as a gel.
3. Fibrin-PTH is undergoing a Phase 2a clinical trial for single level transforaminal lumbar interbody fusion procedures in patients with degenerative disc disease, with autograft as the comparator.
More articles on devices:
8 of the biggest whistleblower cases in spine, orthopedics this year
Outpatient joint replacements to ‘skyrocket over next 10 years,’ says Dr. Richard Berger
Centinel Spine founder leaves to grow other business; Steven Murray named CEO
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
